Press release
Hyperkalemia Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Zeria Pharma, AstraZeneca, Vifor Pharma, Ardelyx
DelveInsight's "Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Hyperkalemia market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Hyperkalemia: An Overview
Hyperkalemia arises when potassium levels in the blood get too high. Potassium is an important nutrient found in foods that helps the nerves and muscles function properly. Too much potassium in the blood can damage the heart, causing a heart attack.
A typical potassium level for an adult falls between 3.5 and 5 millimoles per liter (mmol/L). When levels are above 5.1 mmol/L, it is considered mild hyperkalemia; above 6 mmol/L can be severe, causing heart problems requiring immediate medical attention. Usually, hyperkalemia develops due to increased intake, decreased excretion, or a shift of potassium from the intracellular to the extracellular compartment.
Hyperkalemia Market Key Facts
The market size of Hyperkalemia in the seven major markets was approximately USD 1,198 million in 2021, which is further expected to increase by 2032.
Among the 7MM countries, the US accounted for the highest market size of Hyperkalemia with USD 970 million in 2021, which is likely to increase by 2032.
Among EU4 and the United Kingdom, Germany accounted for USD 49 million in 2021, followed by the United Kingdom with USD 38 million in the same year, while Spain accounted for the lowest market with USD 4 million in 2021.
Japan accounted for USD 127 million in 2021, which is expected to increase by 2032.
In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,046 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019-2032).
Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia, with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.
Discover How Hyperkalemia Market will Grow by 2032:
https://www.delveinsight.com/report-store/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Hyperkalemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hyperkalemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Hyperkalemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hyperkalemia Epidemiology
The epidemiology section covers detailed insights into the historical and current Hyperkalemia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.
Get Key Insights Into the Evolving Hyperkalemia Epidemiology Trends:
https://www.delveinsight.com/report-store/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Epidemiology Segmented as -
Total Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019-2032]
Age-Specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019-2032]
Severity-Specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019-2032]
Gender-Specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019-2032]
Comorbidity-Specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019-2032]
Hyperkalemia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperkalemia market or expected to be launched during the study period. The analysis covers Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Hyperkalemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Leading Players in the Hyperkalemia Therapeutics Market Include:
Zeria Pharmaceutical
AstraZeneca
Vifor Pharma
Ardelyx
And Many Others
Hyperkalemia Therapies Covered in the Report Include:
RDX013: Ardelyx
PATIROMER (ZG-801): Zeria Pharmaceuticals
And Many More
Learn More About the Emerging Therapies & Key Companies in the Hyperkalemia Therapeutics Market:
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hyperkalemia Competitive Intelligence Analysis
4. Hyperkalemia Market Overview at a Glance
5. Hyperkalemia Background and Overview
6. Hyperkalemia Patient Journey
7. Hyperkalemia Epidemiology and Patient Population
8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hyperkalemia Unmet Needs
10. Key Endpoints of Hyperkalemia Treatment
11. Hyperkalemia Marketed Products
12. Hyperkalemia Emerging Therapies
13. Hyperkalemia Seven Major Market Analysis
14. Attribute Analysis
15. Hyperkalemia Market Outlook (7 major markets)
16. Hyperkalemia Access and Reimbursement Overview
17. KOL Views on the Hyperkalemia Market.
18. Hyperkalemia Market Drivers
19. Hyperkalemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Reports by DelveInsight-)
- Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
- Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
- Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
- Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
- Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market
- Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
- Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
- Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market
- Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market
- Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market
- Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market
- Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
- Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market
- Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperkalemia Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Zeria Pharma, AstraZeneca, Vifor Pharma, Ardelyx here
News-ID: 3033648 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Hyperkalemia
Hyperkalemia Japan Market to Reach USD 1.37 Billion by 2034
Hyperkalemia-a condition characterized by elevated potassium levels in the blood-represents a critical challenge in Japan's healthcare landscape. With the nation's rapidly aging population and rising incidence of chronic kidney disease (CKD), heart failure, and diabetes, effective management of hyperkalemia is becoming increasingly vital. Left untreated, hyperkalemia can lead to life-threatening cardiac arrhythmias, making timely diagnosis and treatment essential.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71975
According to Exactitude Consultancy,…
Global Hyperkalemia Treatment Market Research Report 2023
Hyperkalemia Treatment Market Size
The global Hyperkalemia Treatment market was valued at US$ 540 million in 2022 and is anticipated to reach US$ 2068.8 million by 2029, witnessing a CAGR of 20.9% during the forecast period 2023-2029.
Hyperkalemia Treatment Market
Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating…
Hyperkalemia Market to Reach US$ 2,320.5 Million by 2033 | IMARC Group
The newly published report by IMARC Group, titled "Hyperkalemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the hyperkalemia market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements…
Hyperkalemia Treatment Market Size, Share, Industry, Forecast to 2030
The Hyperkalemia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Hyperkalemia Treatment market. This report explores all the key factors affecting the growth of the global Hyperkalemia Treatment market, including…
Hyperkalemia Treatment Market 2022-2028 Global Industry Development Trends and A …
The latest Hyperkalemia Treatment Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Hyperkalemia Treatment Market.
Kidneys…
Global Hyperkalemia Supplement Market, Size, Share, Analysis Report & Forecast t …
The global hyperkalemia treatment market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing chronic diseases such as acute hyperkalemia and chronic hyperkalemia due to other ailments such as diabetes, consumption of high potassium diets, and many other things. As per the National Kidney Foundation, more than 37 million people in the United States have…
